Simvastatina

Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 4

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 5

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 3

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 2

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 1

Organic anion transporting polypetide1B1

Pharmacogenomics insights into treatment and management of statin-induced myopathy

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics

Lipidomic analysis of variation in response to simvastatin in

FDA - limit use of 80 mg simvastatin

PharmaGKB very important pharmacogene- SLCO1B1

Pharmacogenomics- the genetics of variable drug responses

Transporter Pharmacogenetics and Statin Toxicity

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Different Effects of SLCO1B1 Polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin

Differential effect rs4149056 variant SLCO1B1 on myopathy associated with

SLCO1B1 variants and statin-induced myopathy - a genomewide study

The SLCO1B1-5 genetic variant is associated with statin-induced side effects

Combined influence of LDLR and HMGCR sequence varation on lipid-lowering response to simvastatin

CPIC Guideline for SLCO1B1 and simvastatin-induced myopathy supplemental material

CPIC Guideline for SLCO1B1 and simvastatin-induced myopaty

CPIC Guideline for SLCO1B1 and Simvastatin-induced myopathy-supplemental table 6

CPIC Guiline for SLCO1B1 and Simvastatin-induced myopahty-supplemental table 7